NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data ...

Headwaters Capital Management, an investment management company, released its fourth-quarter 2024 investor letter. A copy of ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

So What: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is ...

TransMedics Gr TMDX has outperformed the market over the past 5 years by 12.34% on an annualized basis producing an average ...

TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as ...

JP Morgan has recently reduced TransMedics Group Inc (TMDX) stock to Neutral rating, as announced on December 17, 2024, according to Finviz. Earlier, on November 22, 2024, Needham had reduced the ...

The law firm of Kirby McInerney LLP is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the“Company”) (NASDAQ:TMDX). The investigation concerns whether TransMedics ...

TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.